Metformin in combination with chemoradiotherapy in locally advanced non–small cell lung cancer: The OCOG-ALMERA randomized clinical trial
T Tsakiridis, GR Pond, J Wright, PM Ellis… - JAMA …, 2021 - jamanetwork.com
Importance Unresected locally advanced non–small cell lung cancer (LA-NSCLC) shows
poor survival outcomes even after aggressive concurrent chemoradiotherapy. Whether …
poor survival outcomes even after aggressive concurrent chemoradiotherapy. Whether …
Addition of metformin to concurrent chemoradiation in patients with locally advanced non–small cell lung cancer: The NRG-LU001 phase 2 randomized clinical trial
Importance Non–small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin
has significant data supporting its use as an antineoplastic agent. Objective To compare …
has significant data supporting its use as an antineoplastic agent. Objective To compare …
Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent …
KCJ Wink, JSA Belderbos, EMT Dieleman… - Radiotherapy and …, 2016 - Elsevier
Background and purpose The aim was to investigate whether the use of metformin during
concurrent chemoradiotherapy (cCRT) for locally advanced non-small cell lung cancer …
concurrent chemoradiotherapy (cCRT) for locally advanced non-small cell lung cancer …
A randomized phase II study of metformin plus paclitaxel/carboplatin/bevacizumab in patients with chemotherapy‐naïve advanced or metastatic nonsquamous non …
KA Marrone, X Zhou, PM Forde, M Purtell… - The …, 2018 - academic.oup.com
Background In the absence of a targeted oncogenic driver mutation or high programmed
death‐ligand 1 expression, systemic therapy with platinum‐based doublet chemotherapy …
death‐ligand 1 expression, systemic therapy with platinum‐based doublet chemotherapy …
Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor–mutated lung …
O Arrieta, F Barrón, MÁS Padilla, A Avilés-Salas… - JAMA …, 2019 - jamanetwork.com
Importance Metformin hydrochloride is emerging as a repurposed anticancer drug.
Preclinical and retrospective studies have shown that it improves outcomes across a wide …
Preclinical and retrospective studies have shown that it improves outcomes across a wide …
[HTML][HTML] Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: A multicentre, open-label phase I–II study of metformin with …
Purpose Our previous works demonstrated the ability of metformin to revert resistance to
gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in …
gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in …
Survival of patients with stage IV lung cancer with diabetes treated with metformin
JJ Lin, EJ Gallagher, K Sigel, G Mhango… - American journal of …, 2015 - atsjournals.org
Rationale: Prior studies have shown an anticancer effect of metformin in patients with breast
and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in …
and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in …
Prognostic influence of metformin as first‐line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes
BX Tan, WX Yao, J Ge, XC Peng, XB Du, R Zhang… - Cancer, 2011 - Wiley Online Library
BACKGROUND: It has been reported that antidiabetic drugs affect the risk of cancer and the
prognosis of patients with diabetes, but few studies have demonstrated the influence of …
prognosis of patients with diabetes, but few studies have demonstrated the influence of …
A clinical update on metformin and lung cancer in diabetic patients.
G Gupta, T de Jesus Andreoli Pinto… - Panminerva …, 2018 - europepmc.org
Diabetes mellitus (DM) is frequently increased in many countries and become a serious
health problem worldwide. Diabetes is associated with dysfunction of different organs such …
health problem worldwide. Diabetes is associated with dysfunction of different organs such …
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes
H Chen, W Yao, Q Chu, R Han, Y Wang, J Sun… - Cancer letters, 2015 - Elsevier
Background Acquired resistance has become the bottleneck affecting the efficacy of
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. Studies …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. Studies …
相关搜索
- chemo radiotherapy lung cancer
- combination with chemoradiotherapy ocog almera
- chemo radiotherapy consolidation chemotherapy
- consolidation chemotherapy lung cancer
- metformin therapy survival benefit
- chemo radiotherapy pooled analysis
- lung adenocarcinoma effect of metformin
- metformin in combination treatment of patients
- pooled analysis lung cancer
- metformin in combination synergistic effects
- metformin in combination egfr tki
- metformin in combination ocog almera